There were 1,852 press releases posted in the last 24 hours and 427,329 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image